BioSpace News Archive

Personalis, Inc., a leader in advanced genomics for cancer, announced today it will release its fourth quarter 2020 financial results after the market closes on Thursday, February 25, 2021.

The defining challenge of this century will be to meet the energy needs of a global population expected to reach nearly 10 billion by 2050 while slashing the balance of planet-warming greenhouse gases entering the atmosphere to nearly zero.

NCCN, ACS CAN, and NMQF present new polling data showing patient, caregiver and provider views of bias and suggest policy and practice changes to improve equity in access to high quality cancer care.

Cedarville University’s school of nursing is one of five nursing schools in Ohio to win the 2019-20 Hall of Fame award for its End-of-Life Nursing Education Consortium curriculum.

Bexion Pharmaceuticals, Inc. announced today that it has added Olivia F. Kirtley to its Board of Directors. Ms. Kirtley, a Certified Public Accountant and Chartered Global Management Accountant,

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release fourth quarter financial results after the close of trading on Monday, March 1, 2021.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the closing of its public offering of 2,804,878 shares of its common stock,

Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will expand clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin.

Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which takes place March 1-4, 2021. Ron Rocca, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, March 3 at 4:00 pm EST.

Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call